POTASSIUM CHLORIDE 0.075% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinical safety rating: safe
No significant drug interactions Can cause hypernatremia and fluid overload.
Potassium chloride is a potassium supplement that replaces intracellular potassium, maintaining cellular membrane potential, acid-base balance, and nerve conduction. Sodium chloride provides isotonicity and replaces sodium and chloride ions.
| Metabolism | Potassium is primarily excreted unchanged by the kidneys (90%) via glomerular filtration and tubular secretion, with minor excretion in feces. Sodium and chloride are also renally excreted. |
| Excretion | Primarily renal (>90% excreted unchanged in urine); minimal fecal/biliary elimination. |
| Half-life | No true elimination half-life in classic sense; potassium is rapidly distributed and eliminated via renal excretion with a functional half-life of approximately 8-12 hours in patients with normal renal function. |
| Protein binding | Not significantly protein-bound; <5% bound, predominantly to albumin. |
| Volume of Distribution | Approximately 0.5 L/kg (total body water); distributes primarily into intracellular space (98% of total body potassium is intracellular). |
| Bioavailability | Oral: 90-100% (well absorbed); IV: 100%. |
| Onset of Action | IV: Immediate; oral: 30-60 minutes. |
| Duration of Action | IV: Several hours; oral: 4-6 hours for plasma levels, but intracellular repletion may require prolonged administration. |
Intravenous infusion: Potassium chloride 0.075% (7.5 mEq/L) in sodium chloride 0.9% at a rate of 100-200 mL/hour (0.75-1.5 mEq K+/hour). Typical adult dose: 7.5-15 mEq potassium per day via continuous infusion.
| Dosage form | INJECTABLE |
| Renal impairment | GFR >50 mL/min: No adjustment. GFR 30-50 mL/min: Reduce infusion rate by 25-50% and monitor potassium closely. GFR <30 mL/min: Avoid use or use with extreme caution; consider alternative therapy. Requires frequent serum potassium monitoring. |
| Liver impairment | Child-Pugh A: No adjustment. Child-Pugh B: Monitor potassium levels due to risk of hyperkalemia from reduced clearance. Child-Pugh C: Use with caution; consider reduced infusion rate and frequent monitoring. |
| Pediatric use | Weight-based: 0.5-1 mEq/kg/day of potassium as continuous IV infusion. Maximum infusion rate: 0.5 mEq/kg/hour. For 0.075% solution, adjust volume accordingly to deliver desired potassium dose. Monitor serum potassium and ECG. |
| Geriatric use | Elderly patients: Use lower initial infusion rates (e.g., 50-100 mL/hour) due to age-related decline in renal function. Monitor renal function and serum potassium closely. Avoid rapid infusion to prevent hyperkalemia. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
No significant drug interactions Can cause hypernatremia and fluid overload.
| FDA category | Animal |
| Breastfeeding | Potassium and chloride are normal constituents of breast milk. Exogenous administration does not significantly alter milk composition. M/P ratio not applicable; no adverse effects reported in breastfed infants. Compatible with breastfeeding. |
| Teratogenic Risk | Potassium chloride and sodium chloride do not have intrinsic teratogenic potential. However, hyperkalemia or hypokalemia during pregnancy can cause fetal arrhythmias or growth disturbances. First trimester: no specific structural risks. Second/third trimester: electrolyte disturbances may affect fetal development; maintain normal maternal potassium levels. |
■ FDA Black Box Warning
None.
| Common Effects | fluid replacement |
| Serious Effects |
["Hyperkalemia","Severe renal impairment (oliguria, anuria)","Acute dehydration","Concurrent use of potassium-sparing diuretics","Hypersensitivity to any component"]
| Precautions | ["Risk of hyperkalemia, especially in renal impairment or with rapid infusion","Use with caution in patients with cardiac disease, adrenal insufficiency, or metabolic acidosis","Monitor serum potassium and ECG during administration","Extravasation risk; avoid infiltration","Do not administer undiluted or via IV push"] |
Loading safety data…
| Fetal Monitoring | Monitor serum potassium, sodium, and chloride levels periodically, especially during prolonged infusion. Assess fluid balance and signs of hyperkalemia (ECG changes, muscle weakness) or hypernatremia. Fetal monitoring is not required unless maternal electrolyte disturbances occur. |
| Fertility Effects | No known adverse effects on fertility. Normal electrolyte balance is essential for reproductive function; severe disturbances may theoretically impair ovulatory or spermatogenic processes. |